Selected article for: "add therapy and dose dependent manner"
Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
  • Document date: 2020_3_24
    • ID: 6g34qwer_37
    Snippet: In our recent published study, we have revealed that CD147 is a novel identified receptor for SARS-CoV-2 infection by binding with spike protein. SARS-CoV-2 infection was efficiently inhibited by meplazumab targeting CD147 in a dose dependent manner. All these results provide insights that CD147 acts as a functional entry receptor for SARS-CoV-2, and serves as a therapeutic target for inhibiting virus infection. 13 It was reported 18.5% cases in .....
    Document: In our recent published study, we have revealed that CD147 is a novel identified receptor for SARS-CoV-2 infection by binding with spike protein. SARS-CoV-2 infection was efficiently inhibited by meplazumab targeting CD147 in a dose dependent manner. All these results provide insights that CD147 acts as a functional entry receptor for SARS-CoV-2, and serves as a therapeutic target for inhibiting virus infection. 13 It was reported 18.5% cases in COVID-19 were categorized as severe and critical cases, and fatality rate for critical case was 49.0% to 61.5%. 4, 8 These studies reveal the great challenge of enhancing the therapeutic effects for severe case of COVID-19, and focus on how to conduct effective intervention as early as possible. In this add-on trial, we introduced a novel therapy target to block the virus infection and inflammation, with a favorable efficacy. Meplazumab treatment accelerated the improvement of COVID-19, especially in the severe and critical cases. At the day 28, 69.2% severe and critical cases were discharged, and no death case was reported. The improvement of chest imaging, clearance of virus, and recovering of lymphocyte count, were observed within 1 week management, which indicated that the therapeutic effects facilitated prognosis.

    Search related documents:
    Co phrase search for related documents
    • chest imaging and death case: 1, 2, 3, 4
    • chest imaging and effective intervention: 1, 2
    • chest imaging and entry receptor: 1
    • chest imaging and fatality rate: 1, 2, 3, 4, 5
    • critical case and death case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • critical case and death case report: 1
    • critical case and dependent manner: 1
    • critical case and effective intervention: 1
    • critical case and entry receptor: 1
    • critical case and fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • critical case fatality rate and effective intervention: 1
    • critical case fatality rate and fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • critical severe case and death case: 1, 2, 3, 4, 5, 6
    • critical severe case and fatality rate: 1, 2, 3, 4, 5, 6
    • death case and entry receptor: 1
    • death case and fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • dependent manner and dose dependent manner: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • dependent manner and effective intervention: 1
    • dependent manner and efficiently inhibit: 1